Hereditary Cancer Syndrome Clinical Trial
— CHARMOfficial title:
Exome Sequencing in Diverse Populations in Colorado & Oregon
Verified date | June 2022 |
Source | Kaiser Permanente |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The CHARM (Cancer Health Assessment Reaching Many) study will assess the utility of clinical exome sequencing and how it affects care in diverse populations. The study population includes adults at risk for hereditary cancer syndromes. The primary objective is to implement a hereditary cancer risk assessment program in healthy 18-49 year-olds in primary care settings within a vertically integrated health delivery system (Kaiser Permanente) and a federal qualified health center (Denver Health). The investigators will assess clinical exome sequencing implementation and interpretation, as well as tailored interactions for low health literacy including a contextualized consent process, and a modified approach to results disclosure and genetic counseling. The investigators will also assess the clinical utility (healthcare utilization and adherence to recommended care) and personal utility of primary and additional results from clinical exome sequencing, and evaluate the ethical and policy implications of considering personal utility of genomic information decisions for health care coverage.
Status | Active, not recruiting |
Enrollment | 967 |
Est. completion date | December 31, 2023 |
Est. primary completion date | August 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: - Kaiser Permanente Northwest or Denver Health patient - Screens as high risk for a hereditary cancer syndrome via the risk assessment tool algorithms OR have unknown family history on either their mother or father's side of the family (or both) - No known prior testing for familial mutations predisposing them to Lynch syndrome or hereditary breast and ovarian cancer - English or Spanish speaker Exclusion Criteria: - Participant self-reported prior testing for Lynch syndrome (LS) or Hereditary Breast and Ovarian Cancer (HBOC) syndrome or identified as having previous comprehensive testing via Kaiser Permanente data files - Not an English or Spanish speaker - Unable to provide informed consent - Don't want results placed in their medical record |
Country | Name | City | State |
---|---|---|---|
United States | Denver Health | Denver | Colorado |
United States | Kaiser Permanente Center for Health Research | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Kaiser Permanente | Columbia University, Dana-Farber Cancer Institute, Denver Health and Hospital Authority, Emory University, National Human Genome Research Institute (NHGRI), Seattle Children's Hospital, University of California, San Francisco, University of Washington |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive findings for hereditary cancer syndromes | Number of people found to have a pathogenic variant in one of the cancer genes associated with Lynch syndrome or hereditary breast and ovarian cancer | Within one month of specimen receipt at the laboratory | |
Secondary | Positive findings for other medically actionable genetic conditions | Number of people with pathogenic variants found in genes related to medically actionable hereditary conditions | Within one month of specimen receipt at the laboratory | |
Secondary | Positive findings for a selected list of carrier conditions | Number of people with pathogenic variants found in genes related to common carrier conditions | Within one month of specimen receipt at the laboratory | |
Secondary | Comparison of Healthcare Utilization measured via Electronic Medical Record (EMR) data | Downstream healthcare utilization of specific recommended procedures (e.g., colonoscopy, mammography, surgery) will be compared between participants in the traditional genetic counseling arm, the modified genetic counseling arm, and patients at high risk for a hereditary cancer syndrome that do not join the study (usual care) | Within 12 months of participant receiving information about their hereditary cancer syndrome risk | |
Secondary | Participant understanding of recommended care | Measurement of participant's understanding of the recommended care based on their genetic test result will be assessed using a validated survey tool | 2 weeks post result disclosure, 6 months post result disclosure | |
Secondary | Participant understanding of genetic test results | Measurement of patient's understanding of the genetic test results will be assessed using a validated survey tool | 2 weeks post result disclosure, 6 months post result disclosure | |
Secondary | Participant satisfaction of genetic counseling | Measurement of the patient's satisfaction of genetic counseling will be assessed using a validated survey tool | 2 weeks post result disclosure, 6 months post result disclosure | |
Secondary | Family communication | Measurement of the degree to which participants shared their genetic test results with various family members will be assessed using a validated survey tool | Baseline, 2 weeks post result disclosure, 6 months post result disclosure | |
Secondary | Personal utility | Measurement of the participant's perceived utility of obtaining genetic testing and counseling will be assessed using validated survey tools that assess lifestyle behaviors and self-reported health/quality of life. | Baseline, 2 weeks post result disclosure, 6 months post result disclosure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04541654 -
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
|
||
Active, not recruiting |
NCT03857594 -
Integrative Sequencing In Germline and Hereditary Tumours
|
||
Enrolling by invitation |
NCT05721326 -
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
|
N/A | |
Recruiting |
NCT04261972 -
Cell-free DNA in Hereditary And High-Risk Malignancies
|
||
Recruiting |
NCT05562778 -
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
|
N/A | |
Withdrawn |
NCT05664867 -
Implementation of Population Breast Cancer Genetic Services in Federally Qualified Health Centers (FQHC)
|
N/A | |
Not yet recruiting |
NCT03979612 -
Evaluation of the Adhesion to the GENEPY Network
|